

Mirae Asset Healthcare Fund

Sectoral/Thematic: An open ended equity scheme investing in healthcare and allied sectors.

INVEST IN A POTENTIALLY HEALTHY FUND

Data as on 31st March, 2024

HERE'S WHY YOU SHOULD CONSIDER INVESTING

- Investment for long term
- Flexibility to invest across market capitalisation & styles
- Healthcare is an evolving theme which has growth potential and covers business in the following sectors:

| | | | |
|------------------------|----------------------------|------------------|------------------|
| Pharmaceuticals | Healthcare Services | Insurance | Chemicals |
|------------------------|----------------------------|------------------|------------------|

INVESTMENT DETAILS

- Allotment Date:** 2nd July, 2018
- Benchmark:** S&P BSE Healthcare Index (TRI)
- Net AUM as on 31st March, 2024:** (INR Crs.) 2,235.15

INVESTMENT FRAMEWORK

- The endeavour is to maintain a concentrated portfolio of 30 (+/- 5) stocks.
- Generally the fund has the flexibility to invest across market capitalisation and style in selecting investment opportunities within this theme.

PORTFOLIO PSYCHOGRAPHICS



PORTFOLIO

| | |
|---------------------------|--------|
| Number of Stocks (Equity) | 32 |
| Top 10 Stock % | 67.26% |
| Top 5 Sectors % | 99.58% |






RISK RATIOS

| | |
|--------------------------|------------|
| Beta | 0.91 |
| Alpha | -0.39% |
| Sharpe Ratio | 0.68 |
| Portfolio Turnover Ratio | 0.28 Times |



MARKET CAPITALIZATION

- Large Cap
- Mid Cap
- Small Cap
- Cash



| Stocks | % Allocation |
|---|--------------|
| Sun Pharmaceutical Industries Limited | 14.92% |
| Cipla Limited | 9.62% |
| Aurobindo Pharma Limited | 8.25% |
| Dr. Reddy's Laboratories Limited | 7.17% |
| Apollo Hospitals Enterprise Limited | 6.34% |
| J B Chemicals and Pharma Ltd | 4.61% |
| Krishna Institute Of Medical Sciences Limited | 4.23% |
| Lupin Limited | 4.20% |
| Gland Pharma Limited | 4.10% |
| Torrent Pharmaceuticals Limited | 3.83% |

| Stocks | Mar 2024 | Feb 2024 |
|---------------------------------|----------|----------|
| Pharmaceuticals & Biotechnology | 76.53% | 77.62% |
| Healthcare Services | 19.91% | 18.27% |
| Chemicals & Petrochemicals | 1.78% | 2.03% |
| Insurance | 1.35% | 1.32% |

MARKET OUTLOOK^

- 2023 was characterised by continual of the rate hike cycle by major central banks barring economies like - China and Japan. While US economy defied expectations of a soft or hard landing, other economies like - Europe and UK grappled with the adverse impact of monetary tightening on the economic growth.
- Containing and bringing inflation within the targeted levels still remains the top priority for US, Europe and UK. While inflation in these economies has moderated significantly, it still remains above their comfort zone. The timing and quantum of rate cuts going into 2024 would be keenly watched by financial markets.
- An extended rate hike cycle may lead to unintended consequences and adversely impact the global economic growth. On the other hand, a premature reversal in rate cycle may lead to the core issue (inflation) remaining unaddressed in entirety.

IDEAL INVESTMENT PROFILE



Goal:
Aim for Wealth Generation



Investment Time Horizon:
5 Years +



Risk Profile:
Aggressive



Fund Manager: Mr. Vrijesh Kasera (since 02nd July, 2018)



SIP Amount: Monthly and Quarterly: Minimum ₹500/- (multiples of 1/- thereafter), minimum 5 in case of Monthly / Quarterly option.



Minimum Investment Amount: ₹5,000/- and in multiples of 1/- thereafter. Minimum Additional Application Amount: ₹1,000/- per application and in multiples of 1/- thereafter."



Plans and options: Regular Plan and Direct Plan with Growth and Payout of Income Distribution cum Capital Withdrawal option/Reinvestment of Income Distribution cum Capital Withdrawal option.

FUND DETAILS

PRODUCT LABELLING

Mirae Asset Healthcare Fund is suitable for investors who are seeking*

- To generate long term capital appreciation
- Investments in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sector in India

*Investors should consult their financial advisors, if they are not clear about the suitability of the product.

**Pursuant to Clause 2.7 of Part IV of SEBI Master Circular dated May 19, 2023, the universe of "Mid Cap" shall consist of 101st to 250th company, Large Cap" shall consist of top 100 companies, Small Cap shall consist of 251st and onwards companies in terms of full market capitalization.

#Pursuant to Clause 5.1 of SEBI Master Circular dated May 19, 2023, The sector(s)/stock(s)/issuer(s) mentioned in this presentation do not constitute any research report/recommendation of the same and the fund may or may not have any future position in these sector(s)/stock(s)/issuer(s) For complete portfolio of the scheme, please visit the website <https://www.miraeassetmf.co.in/downloads/portfolio>.

^^Pursuant to notice cum addendum no. 69/2023, Minimum Systematic Investment Plan (SIP) Installment amount for certain Schemes has been Changed with effect from January 01, 2024.

*Portfolio may or may not remain the same. For complete monthly portfolio, please visit the website: [miraeassetmf.co.in/downloads/portfolio](https://www.miraeassetmf.co.in/downloads/portfolio).

***Disclaimer:** Views expressed by the Fund Manager cannot be construed to be a decision to invest. The statements contained herein are based on current views and involve known and unknown risks and uncertainties. Whilst Mirae Asset Investment Managers (India) Private Limited (the AMC) shall have no responsibility/liability whatsoever for the accuracy or any use or reliance thereof of such information. The AMC, its associate or sponsors or group companies, its Directors or employees accept no liability for any loss or damage of any kind resulting out of the use of this document.

Follow us on     

Please consult your financial advisor or Mutual Fund Distributor for more details

Mutual fund investments are subject to market risks, read all scheme related documents carefully.